Supplementary
sICAM-1 † sICAM-1 (291.00 ng/mL) † ACR50/70, American College of Rheumatology 50%/70% improvement; BAFF, B cell-activating factor; CDAI, clinical disease activity index; C1M, collagen type I MMP-cleaved fragment; CRP, C-reactive protein; CXCL, chemokine, CXC motif, ligand; DAS28-CRP, 28-joint disease activity score by CRP; IL-8, interleukin 8; LDA, low disease activity; MMP-3, matrix metalloproteinase 3; OC, osteocalcin; OPG, osteoprotegerin; q2w, every 2 weeks; RANKL, receptor activator of nuclear factor-κB ligand; sICAM-1, soluble intercellular adhesion molecule 1; TNFi, tumor necrosis factor inhibitor. a High: > median value; low: ≤ median value. A logistic regression was implemented using treatment group, region at study entry, number of previous TNFi, and baseline biomarker as fixed effects and baseline biomarker-by-treatment group interaction. Unadjusted P values for the interaction for each treatment group were calculated; all P<0.05. *Predictive of response to sarilumab 150 mg q2w. † Predictive of response to sarilumab 200 mg q2w.
